Amicogen, Inc.
Financials
Valuation Metrics
Amicogen, Inc.'s Market Cap is ₩644B. At end of 2025 it was ₩1259B. Ranked #1528 of 2,410 in KR market (top 63%), #889 of 1,631 on KOSDAQ (top 55%), #168 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 73%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 64.44B KRW | KR#1,528/2,410 Sec#168/231 |
| Revenue | 46.69B KRW | KR#1,831/2,410 Sec#128/231 |
| Net Income | -20.02B KRW | KR—/2,410 Sec—/231 |
| Total Assets | 197.17B KRW | KR#1,321/2,410 Sec#95/231 |
| Net Assets | 118.87B KRW | KR#1,296/2,410 Sec#100/231 |
| Employees | 223 | KR#1,013/2,410 Sec#84/231 |
| Value | ||
| P/B | 0.54x | KR#968/2,410 Sec#53/231 |
| P/S | 1.38x | KR#1,663/2,410 Sec#97/231 |
| FCF Yield | -43.66% | KR—/2,410 Sec—/231 |
| Profitability | ||
| ROE | -16.84% | KR#2,053/2,410 Sec#160/231 |
| ROA | -10.16% | KR#2,101/2,410 Sec#160/231 |
| Op. Margin | -27.93% | KR#2,157/2,410 Sec#152/231 |
| Revenue Growth | -60.34% | KR#2,296/2,410 Sec#206/231 |
| Financial Health | ||
| Debt Ratio | 65.87% | KR#1,163/2,410 Sec#139/231 |
| Total Debt | 57.92B KRW | KR#946/2,410 Sec#64/231 |
| FCF | -28.13B KRW | KR#1,967/2,410 Sec#190/231 |
| Cash | 8.24B KRW | KR#1,795/2,410 Sec#158/231 |
| Current Ratio | 1.04x | KR#1,665/2,410 Sec#167/231 |
| Dividend | ||
| Div. Growth | 0.00% | KR—/2,410 Sec—/231 |
| Performance | ||
| 1Y Return | -69.97% | KR#2,278/2,410 Sec#219/231 |
| 1M Return | -7.59% | KR#579/2,410 Sec#61/231 |
| From 52W High | -72.83% | KR#2,143/2,410 Sec#189/231 |
| 1Y MDD | -74.69% | KR#2,135/2,410 Sec#186/231 |
| Trading | ||
| Volume | 369,004 shares | KR#245/2,410 Sec#20/231 |
| Trading Value | 332.9M KRW | KR#1,034/2,410 Sec#114/231 |
| Foreign Own. | 2.62% | KR#1,413/2,410 Sec#132/231 |
| Per Share | ||
| EPS | -283 KRW | KR—/2,410 Sec—/231 |
| BPS | 1,682 KRW | KR#2,149/2,410 Sec#181/231 |
Company Info
Amicogen, established in 2000, is an industrial bio-specialized company that develops and produces special enzymes for pharmaceuticals, biomaterials for pharmaceuticals, and enzyme-based new biomaterials using genetic evolution technology. The company supplies CX enzyme for 7-ACA production to the global market, pursues localization of purification resins and media for antibody biopharmaceuticals, and expands its health functional food business. By securing production technology and promoting its next-generation antibiotic enzyme CDMO business, Amicogen aims to expand its global market through large-scale commercialization of biopharmaceutical materials. Amicogen is headquartered in Jinju-si, Gyeongsangnam-do.